Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLIBRI-GI phase 2 trial of FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in MSS/pMMR BRAF wild-type metastatic colorectal cancer without liver metastases
2025-524215-36-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: authorised.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-524215-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524215-36-00.